Основная статистика
| CIK | 1368514 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ADMA Biologics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 6, 2025 |
Exhibit 10.1 CREDIT AGREEMENT dated as of August 5, 2025 among ADMA BIOLOGICS, INC., as Borrower, The other Loan Parties Party Hereto, The Lenders Party Hereto JPMORGAN CHASE BANK, N.A., as Administrative Agent and TRUIST BANK, as Documentation Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner JPMORGAN CHASE BANK, N.A., MUFG BANK, LTD. and U.S. BANK NATIONAL ASSOCIATION as Joint Lead Arrangers T |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLOG |
|
| August 6, 2025 |
Exhibit 99.1 ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase Excluding a Prior-Year Non-Recurring Item 2Q |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLO |
|
| May 7, 2025 |
Exhibit 99.1 ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Incr |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 28, 2025 |
EXHIBIT 99.1 ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R&D Engine, Spanning Production and Product De |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| March 18, 2025 |
Exhibit 10.11 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between ADMA Biologics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate protection thro |
|
| March 18, 2025 |
AMENDED AND RESTATED PLASMA PURCHASE AGREEMENT Exhibit 10.7 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. AMENDED AND RESTATED PLASMA PURCHASE AGREEMENT THIS AMENDED AND RESTATED PLASMA PURCHASE AGREEMENT (“Agreement”) between Grifols |
|
| March 18, 2025 |
Exhibit 10.8 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. PLASMA PURCHASE AGREEMENT THIS PLASMA PURCHASE AGREEMENT (“Agreement”) between KEDPlasma LLC, a Delaware limited liability compan |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 0001368514false-12-31falseFY202000100000000000593183552390000563035110000060000000013685142020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-02-012021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-01-012021-03-160001368514adma:InventoryPurchasesMemberadma:GrifolsMember2019-01-012019-12-310 |
|
| March 18, 2025 |
Exhibit 19.1 Effective September 2024 INSIDER TRADING POLICY ADMA has adopted the policies and procedures described herein in order to prevent insider trading. The Company prohibits trading based on Material Nonpublic Information regarding the Company or gained during the course of work for the Company. The policy covers all officers, directors, members of the scientific advisory board, employees, |
|
| March 18, 2025 |
EXHIBIT 21.1 ADMA BioCenters Georgia Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioCenters Georgia Inc. ADMA Plasma Biologics, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA Plasma Biologics, Inc. ADMA BioManufacturing, LLC Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioManufac |
|
| March 3, 2025 |
Exhibit 99.1 ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income(2) of $119.2 Million, Com |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 001-36728 CUSIP Number 000899104 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| January 13, 2025 |
Exhibit 99.1 ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2025 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “C |
|
| January 13, 2025 |
Exhibit 99.1 ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More than $100 Million, an Increase of Approximately $45 Million Q-o-Q, Notwithstanding $30 Million of Debt Organically Discharged During 4Q 2024 Ne |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| December 20, 2024 |
Exhibit 99.1 ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA’s Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, FL, December 20, 2024 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd., as the ultimate parent company of each of its undersigned subsidiarie |
|
| November 8, 2024 |
ADMA / ADMA Biologics, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADMA Biologics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 7, 2024 |
Exhibit 99.1 ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update 3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA(1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA B |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 17, 2024 |
ADMA / ADMA Biologics, Inc. / STATE STREET CORP Passive Investment SC 13G 1 ADMABiologicsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADMA BIOLOGICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 000899104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 9, 2024 |
Exhibit 16.1 October 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the disclosures in Item 4.01 of Form 8-K dated October 3, 2024, of ADMA Biologics, Inc. and Subsidiaries and are in agreement with the statements therein. /s/ CohnReznick LLP |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 23, 2024 |
ADMA / ADMA Biologics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADMA BIOLOGICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 000899104 (CUSIP Number) SEPTEMBER 19, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 14, 2024 |
Exhibit 99.1 ADMA Biologics Announces Partial Paydown of Revolving Credit Facility Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers ADMA’s Total Debt to $105 Million, a 22% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, FL, August 14, 2024 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the |
|
| August 8, 2024 |
Exhibit 99.1 ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update 2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA’s Innovative Biologics Manufacturing Process Suppo |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLOG |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 26, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated July 24, 2024 (the “Effective Date”), is entered into by and between ADMA Biologics, Inc., a Delaware corporation (the “Company”), and Brad Tade (“Executive”). STATEMENT OF AGREEMENT Section 1. EMPLOYMENT Section 1.1 Term; At-Will Employment. Executive acknowledges and understands that employment with the Company |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2024 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ADMA BIOLOGICS, INC. (A Delaware Corporation) June 27, 2024 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 1. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 1. Place of Meetings 1 Section 2. Annual Meetings and Advance Notice of Stockholder Nomi |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 17, 2024 |
Exhibit 99.1 ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology May 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Comp |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLO |
|
| May 9, 2024 |
Exhibit 99.1 ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, R |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| April 2, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this "Agreement"), dated April 1, 2024 (the “Effective Date”), is entered into by and between ADMA Biologics, Inc., a Delaware corporation (the "Company"), and Kaitlin Kestenberg ("Executive"). STATEMENT OF AGREEMENT Section 1. EMPLOYMENT Section 1.1 Term; At-Will Employment. Executive acknowledges and understands that employment with th |
|
| March 11, 2024 |
ADMA / ADMA Biologics, Inc. / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) February 29, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| March 11, 2024 |
Exhibit 99.1 ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM® FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM Provides for Improved Inventory Mana |
|
| March 11, 2024 |
ADMA / ADMA Biologics, Inc. / TEACHERS ADVISORS, LLC Passive Investment SC 13G/A 1 c108460sc13ga.htm CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) February 29, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| March 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 11, 2024 |
ADMA / ADMA Biologics, Inc. / Nuveen Asset Management, LLC Passive Investment SC 13G/A 1 c108458sc13ga.htm CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) February 29, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| March 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| March 5, 2024 |
Exhibit 99.1 ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology March 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Co |
|
| February 28, 2024 |
EXHIBIT 21.1 ADMA BioCenters Georgia Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioCenters Georgia Inc. ADMA Plasma Biologics, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA Plasma Biologics, Inc. ADMA BioManufacturing, LLC Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioManufac |
|
| February 28, 2024 |
Exhibit 99.1 ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net Income of $0.7 Million FY 2024 and 2025 Total |
|
| February 28, 2024 |
Exhibit 10.1 Execution Version CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this “Agreement”), is made as of February 27, 2024 and effective as of April 1, 2024 (the “Effective Date”), by and between Brian Lenz, an individual residing at the address in the State of New Jersey on file with the Company (“Consultant”) and ADMA Biologics, Inc., a Delaware corporation (“ADMA Biolog |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 0001368514false-12-31falseFY202000100000000000593183552390000563035110000060000000013685142020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-02-012021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-01-012021-03-160001368514adma:InventoryPurchasesMemberadma:GrifolsMember2019-01-012019-12-310 |
|
| February 28, 2024 |
ADMA Biologics Announces CFO Transition Executive Search Initiated for CFO Replacement Exhibit 99.1 ADMA Biologics Announces CFO Transition Executive Search Initiated for CFO Replacement RAMSEY, N.J. and BOCA RATON, FL, February 28, 2024 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, |
|
| February 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2024 |
ADMA BIOLOGICS, INC. COMPENSATION RECOUPMENT POLICY Exhibit 97 ADMA BIOLOGICS, INC. COMPENSATION RECOUPMENT POLICY I. Defined Terms. (a) “Applicable Rules” means Section 10D of the Exchange Act and Rule 10D-1 promulgated thereunder, Listing Rule 5608 of the Listing Rules of Nasdaq, and any other national stock exchange rules that the Company is or may become subject to. (b) “Clawback Event” means a required recoupment of Incentive-Based Compensatio |
|
| February 21, 2024 |
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics Exhibit 99.1 ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics’ New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling Broader Implementation of ADMAlytics Expected to Provide |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2024 |
ADMA / ADMA Biologics, Inc. / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment SC 13G 1 c108111sc13g.htm CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2024 |
ADMA / ADMA Biologics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 10 4 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 14, 2024 |
ADMA / ADMA Biologics, Inc. / TEACHERS ADVISORS, LLC Passive Investment CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2024 |
EX-99.1 2 d763698dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
ADMA / ADMA Biologics, Inc. / Nuveen Asset Management, LLC Passive Investment CUSIP No. 000899104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ADMA Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 13, 2024 |
ADMA / ADMA Biologics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0185-admabiologicsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: ADMA Biologics Inc Title of Class of Securities: Common Stock CUSIP Number: 000899104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to wh |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 8, 2024 |
Exhibit 99.1 ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjust |
|
| January 8, 2024 |
Exhibit 99.1 ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2024 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “ |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| December 18, 2023 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT SECURITY AGREEMENT, dated as of December 18, 2023, made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Grantors”), in favor of ARES CAPITAL CORPORATION (“Ares”), a Maryland corporation, as collateral agent for the Lenders (in such capacity, together with its successors and a |
|
| December 18, 2023 |
Exhibit 99.1 ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla., Dec. 18, 2023- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a |
|
| December 18, 2023 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT by and among ADMA BIOLOGICS, INC., as Administrative Borrower, ADMA BIOMANUFACTURING, LLC, ADMA PLASMA BIOLOGICS, INC. ADMA BIOCENTERS GEORGIA INC., each as a Borrower Certain Subsidiaries of Administrative Borrower, as Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and ARES CAPITAL CORPORATION, as Administrati |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| December 12, 2023 |
Exhibit 99.1 ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older Signifies the Successful Fulfillment of BIVIGAM’s Post Marketing Commitments as Part of the Original BLA Approval Expanded Label in the U.S. Now Includes Pediatric PI Patients 2 Years of Age and Older RAMSEY, N.J. and BOCA RATON, Fla., Dec. 12, 2023- ADMA Biologics, I |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| November 16, 2023 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency RAMSEY, N.J., BOCA RATON, Fla. and Laurel, MD– Nov. 16, 2023– ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated |
|
| November 8, 2023 |
Exhibit 99.1 ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update 3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to $74.2 Million 3Q2023 Adjusted EBITDA(1) Grew to $12.7 Million, a 98% Q-o-Q Increase FY2023 Tota |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA B |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2023 |
ADMA BIOLOGICS, INC. AND SUBSIDIARIES Exhibit 99.1 ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted EB |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLOG |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 19, 2023 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Dallas, GA. – July 19, 2023 – ADMA Biologics, Inc. (NASDAQ |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| June 6, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| May 22, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
Exhibit 99.1 ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update 1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1), Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLO |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 2, 2023 |
Exhibit 10.1 AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY, dated as of May 1, 2023 (this “Amendment”), by and among ADMA BIOLOGICS, INC., a Delaware corporation (the “Borrower”), the other Credit Parties party hereto, the lenders party hereto (the “Lenders”) and HAYFIN SERVICES LLP, as administrative agent for the Lenders hereunder (in such capacity, together with its successors and assigns in |
|
| May 2, 2023 |
ADMA Biologics Announces Amendment to Credit Agreement Exhibit 99.1 ADMA Biologics Announces Amendment to Credit Agreement . Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. (Nasdaq : ADMA) (“ADMA” or the “Company”), an end-to-end commercial biop |
|
| May 2, 2023 |
WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, EXCEPT AS SET FORTH IN SECTIONS 6.3 and 6.4 BELOW, UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| April 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| March 23, 2023 |
EXHIBIT 21.1 ADMA BioCenters Georgia Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioCenters Georgia Inc. ADMA Plasma Biologics, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA Plasma Biologics, Inc. ADMA BioManufacturing, LLC Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioManufac |
|
| March 23, 2023 |
Exhibit 99.1 ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update 4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second Half of 2023 Conference Call Scheduled for To |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 0001368514false-12-31falseFY202000100000000000593183552390000563035110000060000000013685142020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-02-012021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-01-012021-03-160001368514adma:InventoryPurchasesMemberadma:GrifolsMember2019-01-012019-12-310 |
|
| March 23, 2023 |
Exhibit 10.25.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of March 22, 2023 (this “Amendment”), by and among ADMA BIOLOGICS, INC., a Delaware corporation (the “Borrower”), the other Credit Parties party hereto, the lenders party hereto (the “Lenders”) and HAYFIN SERVICES LLP, as administrative agent for the Lenders hereunder (in such capacity, together with its successors and assi |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2023 |
ADMA / ADMA Biologics Inc / TEACHERS ADVISORS, LLC Passive Investment CUSIP No. 000899104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ADMA BIOLOGICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2023 |
ADMA / ADMA Biologics Inc / TIAA CREF INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 c105523sc13ga.htm CUSIP No. 000899104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ADMA BIOLOGICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2023 |
ADMA / ADMA Biologics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 10 4 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 14, 2023 |
ADMA / ADMA Biologics Inc / Nuveen Asset Management, LLC Passive Investment SC 13G/A 1 c105525sc13ga.htm CUSIP No. 000899104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ADMA BIOLOGICS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2023 |
ADMA / ADMA Biologics Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adma Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 8, 2023 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Hammond, LA. – February 8, 2023 – ADMA Biologics, Inc. ( |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| January 17, 2023 |
Exhibit 99.1 ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Rev |
|
| December 9, 2022 |
ADMA / ADMA Biologics Inc / Caligan Partners LP - ADMA BIOLOGICS, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899104 (CUSIP Number) Da |
|
| December 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| December 9, 2022 |
Exhibit 99.1 ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares RAMSEY, N.J. and BOCA RATON, Fla., December 9,2022 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty |
|
| December 7, 2022 |
ADMA Biologics, Inc. 20,979,020 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256643 Prospectus Supplement (To prospectus dated August 3, 2021) ADMA Biologics, Inc. 20,979,020 Shares of Common Stock We are offering 20,979,020 shares of our common stock, par value $0.0001 per share (the “common stock”). Our common stock is listed on the Nasdaq Global Market under the symbol “ADMA.” On December 6, 2022, the last reported s |
|
| December 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| December 7, 2022 |
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock Exhibit 99.1 ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., December 7,2022 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously ann |
|
| December 7, 2022 |
20,979,020 Shares ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 Execution Version 20,979,020 Shares ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENT St. Petersburg, Florida December 7, 2022 Raymond James & Associates, Inc. As Representative of the Several Underwriters listed on Schedule I hereto 880 Carillon Parkway St. Petersburg, Florida 33716 Ladies and Gentlemen: ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, su |
|
| December 6, 2022 |
Exhibit 99.1 ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million RAMSEY, N.J. and BOCA RATON, FL, December 6, 2022 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing spec |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| December 6, 2022 |
Subject to Completion, Dated December 6, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256643 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| December 6, 2022 |
ADMA Biologics Announces Proposed Public Offering of Common Stock Exhibit 99.2 ADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, FL, December 6, 2022 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stoc |
|
| November 9, 2022 |
Exhibit 10.1 AMENDMENT 4 TO THE AMENDED AND RESTATED AGREEMENT FOR SERVICES BETWEEN ADMA BIOMANUFACTURING, LLC AND ARETH LLC This Amendment 4 (?Amendment 4?) to the Amended and Restated Agreement for Services between ADMA BioManufacturing, LLC, a Delaware limited liability company (?ADMA?), and Areth LLC, a New Jersey limited liability company (?ARETH?), is effective as of October 18, 2022. ADMA a |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| November 9, 2022 |
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Growth and Narrowing Net Losses Expected into 2023 Conference Ca |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA B |
|
| October 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 31, 2022 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. ? October 31, 2022 ? ADMA Biologic |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLOG |
|
| August 10, 2022 |
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update 2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 S-8 1 brhc10039578s8.htm S-8 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 56-2590442 (State or other jurisdiction of (I.R.S. Employ |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 S-8 POS 1 brhc10039577s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. 333-204590 Registration No. 333-220058 Registration No. 333-224492 Registration No. 333-229921 Registration No. 333-237658 Registration No. 333-254770 Registration No. 333-263345 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendme |
|
| July 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables (1) Form S-8 (Form Type) ADMA Biologics, Inc. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 S-8 POS 1 brhc10039577s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. 333-204590 Registration No. 333-220058 Registration No. 333-224492 Registration No. 333-229921 Registration No. 333-237658 Registration No. 333-254770 Registration No. 333-263345 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendme |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| June 28, 2022 |
ADMA / ADMA Biologics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADMA BIOLOGICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 000899104 (CUSIP Number) JUNE 21, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| June 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| June 27, 2022 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company is on-track to have all 10 plasma collection centers FDA-approved by year-end 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. ? June 27, 2022 ? ADMA Biologics, Inc. |
|
| June 21, 2022 |
ADMA BIOLOGICS, INC. 2022 EQUITY COMPENSATION PLAN Effective June 21, 2022 Exhibit 10.1 ADMA BIOLOGICS, INC. ? 2022 EQUITY COMPENSATION PLAN ? Effective June 21, 2022 The purpose of the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the ?Plan?) is to provide employees of ADMA Biologics, Inc. (the ?Company?) and its Subsidiaries (as defined below), certain consultants and advisors who perform services for the Company or its Subsidiaries, and non-employee members of t |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in it |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2022 |
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update First Quarter 2022 Total Revenues Were Approximately $29. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLO |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| April 28, 2022 |
DEFA14A 1 ny20003524x3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary P |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 90549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, For Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy Statement ?? Definitive Additional Materials ?? Soliciting Material under Rule 14a-12 ADMA BIOLOGICS, INC. |
|
| March 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 25, 2022 |
Exhibit 99.1 ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV? & BIVIGAM? from 24 to 36 Months Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing Extended shelf life ASCENIV & BIVIGAM now commercially available to U.S. healthcare providers RAMSEY, NJ and BOCA RATON, FL ? March 25, |
|
| March 24, 2022 |
Exhibit 10.24 Execution Version CREDIT AGREEMENT AND GUARANTY dated as of March 23, 2022 by and among ADMA BIOLOGICS, INC., as Borrower, THE LENDERS PARTY HERETO, and HAYFIN SERVICES LLP, as the Agent for the Lenders TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 SECTION 1.1 Defined Terms 1 SECTION 1.2 Interpretation 27 SECTION 1.3 Accounting and Financial Determinations 28 SE |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 0001368514false-12-31falseFY202000100000000000593183552390000563035110000060000000013685142020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-02-012021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-01-012021-03-160001368514adma:InventoryPurchasesMemberadma:GrifolsMember2019-01-012019-12-310 |
|
| March 24, 2022 |
EXHIBIT 21.1 ADMA BioCenters Georgia Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioCenters Georgia Inc. ADMA Plasma Biologics, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA Plasma Biologics, Inc. ADMA BioManufacturing, LLC Jurisdiction of incorporation: Delaware Name under which business conducted: ADMA BioManufac |
|
| March 24, 2022 |
Exhibit 99.1 ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater Market Penetration of Higher-Margin Product Mix Completed $175 Mil |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 24, 2022 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, ADMA Biologics, Inc. (the ?Company,? ?we,? or ?our?) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, $0.0001 par value per share (the ?Common Sto |
|
| March 24, 2022 |
Exhibit 4.13 FINAL FORM THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, EXCEPT AS SET FORTH IN SECTIONS 6.3 and 6.4 BELOW, UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM |
|
| March 24, 2022 |
Exhibit 10.25 EXECUTION VERSION SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, supplemented or otherwise modified from time to time, this ?Agreement?), dated as of March 23, 2022, is made by and among ADMA BIOLOGICS, INC., a Delaware corporation (the ?Borrower?), the Subsidiaries of the Borrower named in the signature pages hereto or having joined this Agreement pursuant to Section 23 (ea |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| March 7, 2022 |
Exhibit 107 Exhibit Filing Fees Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0. |
|
| March 7, 2022 |
As filed with the Securities and Exchange Commission on March 7, 2022 As filed with the Securities and Exchange Commission on March 7, 2022 Registration No. |
|
| March 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| March 7, 2022 |
Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by year-end 2023 RAMSEY, N.J., BOCA RATON, Fla. and Conyers, GA. ? March 7, 2022 ? ADMA Bio |
|
| February 15, 2022 |
ADMA / ADMA Biologics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d275761dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 10 4 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) C |
|
| February 15, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
ADMA / ADMA Biologics Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adma Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 11, 2022 |
TEX / Terex Corporation / NWQ INVESTMENT MANAGEMENT COMPANY, LLC Passive Investment SC 13G 1 c103002sc13g.htm CUSIP No. 880779103 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* ADMA BIOLOGICS INC. (Name of Issuer) Common Stock (Title of Class of Se |
|
| February 4, 2022 |
ADMA / ADMA Biologics Inc / Caligan Partners LP - ADMA BIOLOGICS, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899104 (CUSIP Number) David |
|
| January 19, 2022 |
EX-99.1 2 brhc10032870ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full Year 2021 Preliminary Unaudited Total Revenues of Approximately $8 |
|
| January 19, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36728 56-2590442 (State or Other Juris- diction of Incorporation) (Commission |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36728 56-2590442 (State or Other Juris- diction of Incorporation) (Commission |
|
| January 18, 2022 |
EX-99.1 2 brhc10032849ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 RAMSEY, N.J., BOCA RATON, Fla. and GOOSE CREEK, SC. – January 18, 2022 – ADMA Biologics, Inc. (NASDAQ: ADMA) |
|
| December 30, 2021 |
ADMA / ADMA Biologics Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adma Biologics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 000899104 (CUSIP Number) December 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 56-2590442 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4 |
|
| December 21, 2021 |
15-12B 1 brhc1003204315-12b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exac |
|
| December 21, 2021 |
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan EX-99.1 4 brhc10032042ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Adopts Limited Duration Stockholder Rights Plan RAMSEY, N.J. and BOCA RATON, Fla., December 21, 2021 – ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors ha |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36728 56-2590442 (State or Other Juris- diction of Incorporation) (Commissio |
|
| December 21, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF ADMA BIOLOGICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) ADMA Biologics, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of the Delaware, as amended (the ?DGCL?), hereby certifies that, pursuant t |
|
| December 21, 2021 |
Exhibit 4.1 RIGHTS AGREEMENT by and between ADMA BIOLOGICS, INC. and CONTINENTAL STOCK TRANSFER AND TRUST COMPANY as Rights Agent, Dated as of December 20, 2021 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of the Rights Agent 10 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 S |
|
| December 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| December 9, 2021 |
EX-99.1 2 brhc10031690ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Provides Update on Global Intellectual Property Portfolio Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces Existing and Pending IP that Provides for ‘Spiking’ IG Pools with Monoclonal Antibodies to Create Novel Hyperimm |
|
| December 1, 2021 |
Exhibit 99.1 ADMA Biologics Realizing the Potential of Plasma-Derived Therapieswith Groundbreaking Immunotechnology December 2021 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, ?we,? ?our? or |
|
| December 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| November 16, 2021 |
Exhibit 99.1 ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction RAMSEY, N.J., BOCA RATON, FL and Myrtle Beach, SC ? November 16, 2021 ? ADMA Biologics, Inc. (NASDAQ: ADMA) (?ADMA? or the ?Company?), an end-to-end commerci |
|
| November 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2021 |
Exhibit 99.1 ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Losses Quarter-Over-Quarter Management to Host Conference Call and Webcast Today at 4:30 p.m. ET R |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA B |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| October 27, 2021 |
ADMA / ADMA Biologics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 10 4 (CUSIP Number) October 22, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| October 27, 2021 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| October 25, 2021 |
Exhibit 99.1 ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters? Option to Purchase Additional Shares RAMSEY, NJ and BOCA RATON, FL, October 25, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced |
|
| October 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 21, 2021 |
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock EX-99.1 3 brhc10029970ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., October 21, 2021 (GLOBE NEWSWIRE) - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-de |
|
| October 21, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 21, 2021 |
50,000,000 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 50,000,000 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENT St. Petersburg, Florida October 21, 2021 Raymond James & Associates, Inc. As Representative of the Several Underwriters listed on Schedule I hereto 880 Carillon Parkway St. Petersburg, Florida 33716 Ladies and Gentlemen: ADMA Biologics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the term |
|
| October 21, 2021 |
ADMA Biologics, Inc. 50,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256643 Prospectus Supplement (To prospectus dated August 3, 2021) ADMA Biologics, Inc. 50,000,000 Shares of Common Stock We are offering 50,000,000 shares of our common stock, par value $0.0001 per share (the ?common stock?). Our common stock is listed on the Nasdaq Global Market under the symbol ?ADMA.? On October 19, 2021, the last reported s |
|
| October 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 20, 2021 |
Subject to Completion, Dated October 20, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256643 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| October 20, 2021 |
ADMA Biologics Announces Proposed Public Offering of Common Stock Exhibit 99.1 ADMA Biologics Announces Proposed Public Offering of Common Stock RAMSEY, N.J. and BOCA RATON, FL, October 20, 2021 - ADMA Biologics, Inc. (Nasdaq: ADMA) (?ADMA? or the ?Company?), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stoc |
|
| October 18, 2021 |
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D. Exhibit 99.1 ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D. RAMSEY, N.J. and BOCA RATON, Fla., October 18, 2021 ? ADMA Biologics, Inc. (Nasdaq: ADMA) (?ADMA? or the ?Company?), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission F |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| October 1, 2021 |
Exhibit 10.1 ADMA BIOLOGICS, INC. FORM OF RETENTION AWARD AGREEMENT THIS RETENTION AWARD AGREEMENT (the "Agreement") is entered into as of September 29, 2021 (the ?Effective Date?), by and between ADMA Biologics, Inc. (the ?Company?) and [] (?Employee?). Employee and the Company are parties to that certain Amended and Restated Employment Agreement, dated as of January 29, 2019, as may be amended f |
|
| October 1, 2021 |
Exhibit 10.2 Amendment to Amended and Restated Employment Agreement This Amendment to the Amended and Restated Employment Agreement (?Amendment?) is entered into and made effective September 29, 2021 (?Amendment Effective Date?) by and between ADMA Biologics, Inc. (?ADMA?) and Adam S. Grossman ("Executive"). RECITALS WHEREAS, Executive and ADMA are parties to that certain Amended and Restated Empl |
|
| October 1, 2021 |
Exhibit 10.3 Execution Version Amendment to Amended and Restated Employment Agreement This Amendment to the Amended and Restated Employment Agreement (?Amendment?) is entered into and made effective September 29, 2021 (?Amendment Effective Date?) by and between ADMA Biologics, Inc. (?ADMA?) and Brian Lenz ("Executive"). RECITALS WHEREAS, Executive and ADMA are parties to that certain Amended and R |
|
| September 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission |
|
| September 3, 2021 |
Exhibit 1.1 DISTRIBUTION AGREEMENT September 3, 2021 Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, Florida 33716 Attention: Stuart Barich Ladies and Gentlemen: ADMA Biologics, Inc., a Delaware corporation (the ?Company?), confirms its agreement with Raymond James & Associates, Inc., as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (?you |
|
| September 3, 2021 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-256643 Prospectus Supplement (To prospectus dated May 28, 2021) Up to $50,000,000 Common Stock We have entered into a Distribution Agreement (the ?Distribution Agreement?) with Raymond James & Associates, Inc. (?Raymond James?), dated September 3, 2021, relating to the sale of shares of our common stock, par value $0.0001 per share (the ?common |
|
| August 17, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 16, 2021 |
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN EX-99.1 2 brhc10028121ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN RAMSEY, N.J., BOCA RATON, Fla. and MARYVILLE, Tenn. – August 16, 2021 – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-d |
|
| August 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 12, 2021 |
Exhibit 99.1 ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM? and NABI-HB? ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healthcare Providers RAMSEY, NJ and BOCA RATON, FL ? August 9, 2021 ? ADMA Biologics, Inc. (NASDAQ: ADMA) (?ADMA |
|
| August 12, 2021 |
Exhibit 99.1 ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $100 Million or |
|
| August 12, 2021 |
EX-99.2 3 brhc10027960ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System RAMSEY, N.J., BOCA RATON, FL and Conyers, GA – August 10, 2021 – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 11, 2021 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE (the ?Agreement?) is made and entered into by and between Dr. James Mond (hereafter ?Employee?) and ADMA Biologics, Inc. on behalf of itself and each of its subsidiaries, affiliates, divisions, predecessors, successors, and assigns (hereinafter referred to collectively as the ?Company? or ?ADMA Biologics?). Pursuan |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36728 ADMA BIOLOG |
|
| August 3, 2021 |
As filed with the Securities and Exchange Commission on August 3, 2021. As filed with the Securities and Exchange Commission on August 3, 2021. Registration No. 333-256643 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizati |
|
| July 30, 2021 |
ADMA Biologics, Inc. 465 State Route 17 South Ramsey, New Jersey 07446 (201) 478-5552 ADMA Biologics, Inc. 465 State Route 17 South Ramsey, New Jersey 07446 (201) 478-5552 July 30, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Deanna Virginio Re: ADMA Biologics, Inc. Registration Statement on Form S-3 Filed May 28, 2021 File No. 333-256643 Ladies and Gentlemen: Pursuant to Rule 461 under the Se |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
|
| July 20, 2021 |
Exhibit 99.1 ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, NJ and BOCA RATON, FL ? July 20, 2021 ? ADMA Biologics, Inc. (NASDAQ: ADMA) (?ADMA?), an end-to-end commercial biopharmaceutical company dedicat |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File |
